Mon, Jul 28, 2014, 7:46 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Amarin Corporation plc Message Board

  • BapchaMan BapchaMan Sep 21, 2000 12:37 PM Flag

    AMRN - unfulfilled promise.....

    I've tracked this dog since it was Ethical
    Holdings PLC.

    Over the past five years, they had
    every opportunity to become a Biovail [BVF], but they
    blew it - big time.

    Why should I trust Amarin
    this time around ? Just because Elan's Tom Lynch is on
    the board ? I like Tom, but I bet ya, he'll be a 100
    times more loyal to ELN than to Amarin.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Bapcha,

      I figured that was what you meant.
      I'm not sure what plans ELN has for
      Ethical's/Amarin's prior Transdermal assets.

      I am still
      waiting on Q3 results. Hopefully soon. I notice that ELN
      benefited from their Quadrant stake. Perhaps their
      investment in AMRN can pan out as



    • "for your sale..." should read "for your sake..."


    • I am ticked off with Elan. They were
      first to market with the Nicotine patch Prostep, and
      have watched Alza grow Duragesic into a serious
      contributor to revenues. ELN botched the $350M SANO
      acquisition, and now you tell me that they have wasted what
      they acquired from Ethical [I thought that in 1996,
      Ethical's patch technology was far superior to Alza's
      absolutely terrible patches].

      For your sale, I hope
      Amarin does OK in the future.


    • Bapcha,

      I know from AMRN's
      announcements that the Transdermal business was sold to Elan.
      I'm not sure about CCBs but I think that is in the
      past as well.

      As the audio invester piece
      indicates their focus seems to be on US Sales & Marketing
      of the products acquired from...ELN.

      hoping Q3 results will demonstrate they know what
      they're doing.



    • New management has quite some plans to increase
      sales and earnings according to a recent interview.
      Fact that this company trades by invitation and is so
      small means no institutional ownership. I liken it to
      being a venture capital investor at this

      But if AMRN managment executes the way they say, no
      telling where we will end up. FWIW interview with
      Chairman and head of US operations is at

      The guy who does the interview manages a technology
      hedge fund

    • Sure, I have posted on the ELN board a few times,
      and now, on the AMRN board. ELN is a 40 plus percent
      shareholder in Amarin, and a few years ago, I lost some 50%
      in Amarin's predecessor - Ethical Holdings

      So, I am curious about what Amarin is upto these days
      - still pushing extended release calcium channel
      blockers, and compounds that they wanted to package into a
      patch ?


    • Bapcha,

      I've floated in and out of the ELN
      board and have noted your posts there for some time.
      You clearly know ELN. I stopped by this board after
      noting that Tom took the chairmanship.

      I don't
      know much about AMRNs past as Ethical, accept what can
      be gleaned from Elan, that it was a dog development
      company. The company says that is no longer the focus
      however and the fact that ELN sold its non-promoted
      products to them seems to bear that out.

      AMRN S&M
      efforts in the US seem to be building and I am inclined
      to watch to see if they can earn some support. I
      agree that Tom's loyalty is correctly with ELN, but I
      bet he wants ELN's investment in AMRN to get its head
      above water and that would mean a nice profit for those
      that bought at these levels.



      • 1 Reply to tartwiththecart
      • Tart:

        I do hope that for your sake that
        you are right. While Ethical declined 90%, I bit the
        bullett about half-way. Back in 1995-1996, Ethical [now
        Amarin] already had extended release Nifedipine,
        Cardizem, Morphine, and had a bunch of patches in clinical
        trials. Maybe they bit on more than they could

        They also sold their stakes in Shire [SHPGY - now a
        high-flier] and Phytopharm at 5x less than what the two trade
        at today.

        Bottom-line: I got out of Ethical
        because I was disgusted. AMRN [I hope for the new
        stockholders] hopefully will do better.


1.54+0.04(+2.67%)Jul 28 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.